Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Jul;26(1):61–64. doi: 10.1111/j.1365-2125.1988.tb03364.x

Ketanserin concentration-effect relationships in individual hypertensive patients.

R Donnelly 1, H L Elliott 1, P A Meredith 1, D M Hughes 1, J L Reid 1
PMCID: PMC1386500  PMID: 3203061

Abstract

1. This study further investigates the relationship between ketanserin concentration and the fall in BP in individual hypertensive patients. 2. An integrated kinetic-dynamic model was used to characterise the response to ketanserin for each individual in terms of BP reduction per unit drug concentration and to describe the temporal discrepancy for the plasma concentration-effect relationship (keq). 3. Using the linear effect model ketanserin concentrations were well correlated with the fall in BP in individual patients. There was a significant reduction in the responsiveness to ketanserin (m) after 1 month: -0.25 mm Hg ng-1 ml-1, compared with -0.47 following the 1st dose. 4. There was a significant increase in keq from 0.49 (1st dose) to 1.86 h-1 (1 month). 5. There was no relationship between the responsiveness to ketanserin and patient age, starting BP or peripheral alpha-adrenoceptor blockade.

Full text

PDF
61

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cameron H. A., Waller P. C., Ramsay L. E. Ketanserin in essential hypertension: use as monotherapy and in combination with a diuretic or beta-adrenoceptor antagonist. Br J Clin Pharmacol. 1987 Dec;24(6):705–711. doi: 10.1111/j.1365-2125.1987.tb03235.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. De Cree J., Verhaegen H., Symoens J. Acute blood-pressure-lowering effect of ketanserin. Lancet. 1981 May 23;1(8230):1161–1162. doi: 10.1016/s0140-6736(81)92331-x. [DOI] [PubMed] [Google Scholar]
  3. Donnelly R., Elliott H. L., Meredith P. A., Reid J. L. Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. Br J Clin Pharmacol. 1987 Nov;24(5):599–606. doi: 10.1111/j.1365-2125.1987.tb03218.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fagard R., Fiocchi R., Lijnen P., Staessen J., Moerman E., de Schaepdryver A., Amery A. Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J. 1984 Feb;51(2):149–156. doi: 10.1136/hrt.51.2.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hedner T., Persson B., Berglund G. A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension. J Cardiovasc Pharmacol. 1985;7 (Suppl 7):S148–S153. doi: 10.1097/00005344-198500077-00042. [DOI] [PubMed] [Google Scholar]
  6. Hedner T., Pettersson A., Persson B. Blood pressure reduction and pharmacokinetics of ketanserin in hypertensive patients. J Hypertens Suppl. 1986 Apr;4(1):S91–S93. [PubMed] [Google Scholar]
  7. Holford N. H., Sheiner L. B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981 Nov-Dec;6(6):429–453. doi: 10.2165/00003088-198106060-00002. [DOI] [PubMed] [Google Scholar]
  8. Persson B., Pettersson A., Hedner T. Pharmacokinetics of ketanserin in patients with essential hypertension. Eur J Clin Pharmacol. 1987;32(3):259–265. doi: 10.1007/BF00607573. [DOI] [PubMed] [Google Scholar]
  9. Van Nueten J. M., Janssen P. A., Van Beek J., Xhonneux R., Verbeuren T. J., Vanhoutte P. M. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther. 1981 Jul;218(1):217–230. [PubMed] [Google Scholar]
  10. Waal-Manning H. J., Brown S. A., Spears G. F., Simpson F. O. Clinical studies with ketanserin in hypertension. J Cardiovasc Pharmacol. 1985;7 (Suppl 7):S154–S158. doi: 10.1097/00005344-198500077-00043. [DOI] [PubMed] [Google Scholar]
  11. Waller P. C., Solomon S. A., Ramsay L. E. Comparison of ketanserin and slow-release nifedipine added to the treatment of hypertensive patients uncontrolled by a thiazide diuretic plus beta-adrenoceptor blocker. Br J Clin Pharmacol. 1987 Nov;24(5):591–597. doi: 10.1111/j.1365-2125.1987.tb03217.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES